Biotech sector faces innovation capital bottleneck
This article was originally published in Scrip
While at first glance it appears that biotech financing is holding up, closer scrutiny of the numbers by Ernst & Young confirms what most biotech executives have been thinking – the funds for backing new innovation are drying up. In its latest annual Beyond Borders survey of the industry, Ernst & Young, the global financial and business advisory firm, warns that the biotech sector will need to adopt new behaviours if it is continue to innovate sustainably.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.